Publications by authors named "Dirk Lars Kienle"
Article Synopsis
- This phase 1 study tested the combination of obinutuzumab and venetoclax for patients with untreated grade 1-3a follicular lymphoma needing systemic therapy, involving 25 participants.
- The recommended treatment plan included venetoclax at 800 mg daily for 6 cycles and obinutuzumab at specified intervals, resulting in only one serious adverse event observed.
- While the treatment showed high overall response rates (up to 87.5%) and good progression-free survival at one and two-and-a-half years, the results led to the decision against further development of this combination therapy for this patient group.
